Logo

BIOX

Bioceres Crop Solutions Corp.

BIOX

Bioceres Crop Solutions Corp. • NASDAQ
$1.72 ▲ 6.17% (+0.10)
Market Cap $108.75 M
52w High $7.44
52w Low $1.20
Dividend Yield 0%
P/E -1.93
Volume 194.66K
Outstanding Shares 63.23M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q4-2025 $74.4M ▲ $39.1M ▲ $-44.3M ▼ -59.543% ▼ $-0.7 ▼ $-10.68M ▼
Q3-2025 $59.596M ▼ $22.541M ▼ $-1.304M ▼ -2.188% ▼ $-0.021 ▼ $6.633M ▼
Q2-2025 $106.8M ▲ $35.885M ▲ $100K ▲ 0.094% ▲ $0.002 ▲ $11.901M ▲
Q1-2025 $92.6M ▼ $34.874M ▲ $-5.5M ▼ -5.94% ▼ $-0.087 ▼ $7.336M ▼
Q4-2024 $124.313M $31.726M $-1.531M -1.231% $-0.025 $9.078M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q4-2025 $34.735M ▼ $763.645M ▼ $468.427M ▲ $262.809M ▼
Q3-2025 $39.346M ▲ $798.214M ▼ $453.238M ▼ $308.713M ▼
Q2-2025 $31.196M ▼ $835.198M ▲ $488.867M ▲ $309.808M ▲
Q1-2025 $38.179M ▼ $827.256M ▼ $481.231M ▼ $309.736M ▼
Q4-2024 $56.169M $850.628M $501.064M $314.009M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q4-2025 $-51.661M ▼ $26.768M ▲ $1.486M ▲ $-25.71M ▼ $-5.762M ▼ $24.587M ▲
Q3-2025 $-1.591M ▼ $23.338M ▲ $-2.502M ▲ $-12.683M ▼ $9.28M ▲ $20.153M ▲
Q2-2025 $143.535K ▲ $-5.357M ▼ $-5.385M ▼ $6.486M ▲ $-3.102M ▲ $-18.052M ▼
Q1-2025 $-6.369M ▼ $5.157M ▼ $271.763K ▲ $-18.798M ▼ $-12.195M ▼ $2.017M ▼
Q4-2024 $-2.081M $23.257M $-295.058K $5.321M $28.112M $17.202M

Five-Year Company Overview

Income Statement

Income Statement Bioceres has grown its sales meaningfully over the past few years, showing that its products are gaining traction. Profitability, however, is still fragile. The company moved from small losses to roughly break-even and even modest profits, but the most recent period slipped back into a noticeable loss. Operating margins had been steadily improving before flattening out, suggesting rising costs or weaker pricing power lately. Overall, this looks like a growth story that is still in transition, with revenue progress but profits not yet firmly established and some recent backtracking.

Balance Sheet

Balance Sheet The balance sheet has expanded steadily as the business has grown, with total assets and shareholder equity both increasing over time. Debt levels have risen but appear balanced against the growing equity base, indicating a moderate use of borrowing rather than extreme leverage. Cash on hand is relatively limited compared to the size of the business, which reduces the financial cushion if conditions worsen. In simple terms, the company has been building scale and strengthening its capital base, but it does not have an abundance of spare liquidity.

Cash Flow

Cash Flow Cash generation has been improving but remains thin. Operating cash flow moved from negative to slightly positive, indicating the core business is close to funding itself, though not yet with much room to spare. Free cash flow has recently edged into positive territory after a series of years in the red, helped by controlled investment spending. Capital expenditures are steady but not aggressive, pointing to disciplined rather than heavy expansion. The overall cash flow profile suggests a company nearing self-sufficiency but still vulnerable to business or funding shocks.

Competitive Edge

Competitive Edge Bioceres occupies a differentiated niche in agricultural inputs, centered on drought-tolerant seeds and biological products. Its HB4 technology in wheat and soy, along with strong positions in inoculants and bio-based crop protection, gives it a clear identity versus traditional chemical-focused rivals. Strategic acquisitions have broadened its product line and distribution into many countries, and its farmer relationships in Latin America are a notable strength. At the same time, it competes against much larger global agrochemical and seed companies, and its success depends on scaling adoption of relatively new technologies and navigating complex regulatory and trade environments.

Innovation and R&D

Innovation and R&D Innovation is at the heart of Bioceres’ strategy. The HB4 platform, which targets drought resilience, is the flagship, backed by a sizable patent portfolio and long development cycles that create barriers to entry. The company is also pushing hard into biological fertilizers and crop protection, as well as digital tools for traceability and farm decision-making. Its R&D model integrates seeds, biological inputs, and data, aiming to offer a full, sustainable package to farmers. The opportunity is significant, but timelines are long and outcomes depend on regulatory approvals, farmer adoption rates, and the company’s ability to turn promising science into reliable, profitable products at scale.

Summary

Bioceres is an innovation-driven agricultural inputs company that has translated its technology into steady revenue growth, but with uneven and still fragile profitability. The balance sheet shows a business that is scaling up with moderate leverage and limited cash buffers, while cash flows are improving yet not comfortably robust. Its competitive edge comes from being an early mover in drought-tolerant crops and biological solutions, supported by patents, acquisitions, and global distribution. However, it operates in a highly competitive, regulated, and cyclical industry, where adoption of new technologies can take time and face setbacks. Overall, Bioceres’ story is one of promising technology and expanding commercial presence, paired with execution, regulatory, and financial risks that remain very much in play.

NEWS

November 12, 2025 · 5:15 PM UTC

Bioceres Crop Solutions Reports Fiscal First Quarter 2026 Financial and Operational Results

Read more

October 30, 2025 · 8:30 AM UTC

Bioceres Crop Solutions to Host Fiscal First Quarter 2026 Financial Results Conference Call on Thursday, November 13, 2025 at 8:30 a.m. Eastern Time

Read more

September 23, 2025 · 7:00 AM UTC

Bioceres Crop Solutions and Colorado Wheat Research Foundation Partner to Advance Climate-Resilient HB4® Wheat in the U.S.

Read more

September 9, 2025 · 6:00 AM UTC

Bioceres Crop Solutions Reports Fiscal Fourth Quarter and Full-Year 2025 Financial and Operational Results

Read more